Research Article

A Novel Defined RAS-Related Gene Signature for Predicting the Prognosis and Characterization of Biological Function in Osteosarcoma

Qin Chen,1 Xueliang Zhou,1 Jianqiang Jin,1 Jiangbiao Feng,2 Zhounan Xu,1 Yunping Chen,1 Haibo Zhao,1 and Zhongchen Li1

1Zhejiang Province People’s Hospital Haining Hospital, Haining, China
2The 903 Hospital of the Chinese People’s Liberation Army, Beijing, China

Correspondence should be addressed to Zhongchen Li; 106046965@qq.com

Received 4 July 2022; Revised 22 July 2022; Accepted 26 July 2022; Published 23 August 2022

Academic Editor: Jinghua Pan

Copyright © 2022 Qin Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Osteosarcoma (OS) is the most common primary bone malignancy in children and adolescents with a high incidence and poor prognosis. Activation of the RAS pathway promotes progression and metastasis of osteosarcoma. RAS has been studied in many different tumors; however, the prognostic value of RAS-associated genes in OS remains unclear. On this basis, we investigated the RAS-related gene signature and explored the intrinsic biological features of OS.

Methods. We obtained RNA transcriptome sequencing data and clinical information of osteosarcoma patients from the TARGET database. RAS pathway-related genes were obtained from the KEGG pathway database. Molecular subgroups and risk models were developed using consensus clustering and least absolute shrinkage and selection operator (LASSO) regression, respectively. ESTIMATE algorithm and ssGSEA analysis were used to assess the tumor microenvironment and immune penetrance between the two groups. A comprehensive review of gene ontology (GO) and KEGG analyses revealed inherent biological functional differences between the two groups. Results. The consistent clustering showed stratification of osteosarcoma patients into two subtypes based on RAS-associated genes and provided a robust prediction of prognosis. A risk model further confirmed that RAS-related genes are the best prognostic indicators for OS patients. GO analysis showed that GDP/GTP binding, focal adhesion, cytoskeletal motor activity, and cell-matrix junctions were associated with the RAS-related model group. Furthermore, RAS signaling in osteosarcoma based on KEGG analysis was significantly associated with cancer progression, with immune function and tumor microenvironment particularly affected. Conclusion. We constructed a prognostic model founded on RAS-related gene and demonstrated its predictive ability. Then, further exploration of the molecular mechanisms and immune characteristics proved the role of RAS-related gene in the dysregulation in OS.

1. Introduction

Although osteosarcoma (OS) is the most frequent type of primary bone cancer among pediatric population, it is a rare type of disease (5.6 cases per million under 15) and accounts for 2% of childhood cancers [1–3]. Osteosarcoma occurs predominantly in adolescents, which corresponds with pubertal development. But another incidence peak occurs in the elderly and is often related to Paget’s disease [4]. The most common site of origin for osteosarcoma has been reported to be epiphysis [5]. If untreated, osteosarcoma has a rapid course of disease progression and >90% of patients died from pulmonary metastases [6].

Standard treatment for osteosarcoma includes surgical resection and adjuvant chemotherapy, resulting in a long-term survival rate of 65–70% [7]. However, for patients with distant metastases at initial presentation, the reported survival rate varies from only 10% to 40% [8]. Since osteosarcoma is an infrequent and aggressive tumor for which treatment has remained unchanged for decades, it is challenging to reduce therapy resistance and improve prognosis of patients with distant metastases. Hence, there is
a necessity to assess the genetic features of this disease and explore novel treatment strategy.

Several genetic alterations have been described in osteosarcoma, such as TP53 mutation and RB1 deletions [9], which are involved in different molecular pathways associated with tumor progression. RAS-related proteins pertain to the family of GTPases, and RAS (HRAS, NRAS, and KRAS) is regarded as oncogene due to its mutations [10]. Alterations and abnormal activations in the RAS pathway are frequently linked with multitude biological events, including abnormal cell proliferation, developmental disorders, and tumorigenesis. Hyperactive RAS signaling pathway has emerged as a major tumorigenesis and is relevant with a high cancer risk in certain tumors [11].

Considering the difficulty of direct targeting of RAS proteins, indirectly inhibiting one of the RAS pathway molecules can be used in therapeutic approaches [12]. Currently, targeting RAS upstream molecule such as tyrosine kinase receptors, or downstream effectors show treatment efficacy both in vitro and in vivo and deserve further investigations in osteosarcoma patients [13–16]. Accordingly, discovery of characteristic RAS-related gene signatures in osteosarcoma may be helpful to reflect tumor heterogeneity and guide individual treatment for patients.

As of now, it is not known how RAS-related gene expression patterns differ among osteosarcoma patients. In the present study, we performed bioinformatics and statistical analyses to identify and validate a RAS-related gene signature in osteosarcoma. Besides, the biology function and intratumoral immune landscape were depicted comprehensively.

2. Methods

2.1. Collection of Datasets on Osteosarcoma. Clinical data and RNA sequencing data regarding osteosarcoma patients were acquired from the clinical data and RNA-seq data of osteosarcoma patients were obtained from the Therapeutic Research to Generate Effective Treatment (TARGET; https://ogc.cancer.gov/programs/target) database, which included a total of 84 samples. RAS pathway-related genes were retrieved through the KEGG pathway database (KEGG pathway: hsa04014 (genome.jp)).

2.2. Recognition of Molecular Subgroups and Time Assessment. At first, a univariate Cox regression analysis was used to identify 14 genes associated with the prognosis of osteosarcoma. Based on the expression matrix from the 14 genes, consensus clustering was performed using the R package “ConsensusClusterPlus.” The calculation of stromal score, immune score, and tumor purity was performed using the algorithm for estimating stromal and immune cells in malignant tissues using expression data (ESTIMATE) [17]. The extent of enrichment of 24 immune infiltrating cells in tumor samples was assessed using single-sample gene set enrichment analysis (ssGSEA) [18].

2.3. Identification of Differentially Expressed RAS-Related Genes. The Limma package version 3.4.3 in R software version 4.0.3 was used to identify DEGs by comparing the mRNA expression of RAS pathway-associated genes between tumor and normal tissues in the TARGET dataset. Those genes with FDR <0.05 and |log2 FC| >0.585 were selected for further analysis.

2.4. Functional Analyses. The differentially expressed genes (DEGs) between both clusters were identified using the R package "Limma." The R package "clusterProfiler" [19] was used for gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis to enrich correlation pathways for visualization in Metascape.

2.5. Establishment of the RAS-Related Gene Prognostic Model. In order to assess the prognostic value of RAS-associated genes, we used additional Cox regression analysis to assess the correlation between each gene and survival status. We set the P value to a critical value of 0.05 to avoid omission and identified 14 survival-associated genes for further analysis. Then, LASSO Cox regression models (R package "glmnet") were used to narrow down the candidate genes and build predictive models.

Finally, five genes and their coefficients were retained, and the penalty parameter (λ) was set according to the minimum criterion. After centralizing and normalizing the gene expression data (using the “scale” function in R), the risk score was calculated with the following formula: risk score = risk score = (0.139 × GNG4 index) + (−1.628 × RAB5C index) + (−0.931 × PRKACB index) + (0.447 × EFNA5 index) + (0.288 × EFNA1 index). OS patients were divided into low and high-risk subgroups according to the median risk score, and the time to OS was compared between the two subgroups by Kaplan–Meier analysis. The predictive efficiency of the model was assessed using the ROC and Martingale residual method.

2.6. Enrichment Analysis of the Function of DEGs between the Low and High-Risk Groups. The patients with OS in the TCGA cohort were stratified into two subgroups based on the median risk score. Screening of DEGs between low and high-risk groups was performed according to specific criteria (|log2FC| ≥1 and FDR<0.05). On the basis of these, DEGs, GO, and KEGG analyses were performed using the software package “clusterProfiler.” The package “gsva” [20] was used to perform ssGSEA, to calculate the fraction of infiltrating immune cells, and to assess the activity of immune-related pathways. The whole process of data analysis is depicted in Figure 1.

2.7. Statistical Analysis. For group comparisons, we applied the Mann–Whitney U test (Shapiro–Wilk test, P < 0.05) for nonnormally distributed data and Student’s t test for...
Sample acquired from TARGET (N=84)

Univariate Cox regression analysis (14↑ gene)

Consensus clustering

Differentially expression analysis

Functional analysis

Lasso regression analysis

Construction of risk model

Survival analysis

Immune infiltrating analysis

Functional analysis

Figure 1: Flow diagram of the data analysis process.

Figure 2: Continued.
Figure 2: Continued.
(c) Targets - OS

(d) Groups

Figure 2: Continued.
normally distributed data. All analyses were performed with R version 4.0.3 (https://www.r-project.org/).

3. Results

3.1. Consensus Clustering of 14 RAS-Related Prognostic Genes Identified Two Clusters of Osteosarcoma. A total of 84 osteosarcoma patients from TARGET cohort were included in the analysis. First, we performed prognostic analysis for all genes, and 784 genes were selected ($P < 0.05$). Subsequently, 14 of 232 RAS-related genes were related to patient survival (Figure 2(a)). Then, the consensus clustering approach was conducted to divide the osteosarcoma patients into subgroups based on 14 RAS-related prognostic genes generated from univariable Cox analysis (Figure 2(a)). The optimal clustering stability was identified when $K = 2$ (Figure 2(b)). 51 patients were clustered into group C1 and 42 patients were clustered into C2. The expression level of the 14 prognostic genes in the two subtypes was visualized through the heatmap (Figure 2(c)), and obvious expression difference was found between C1 and C2. Principal component analysis confirmed that osteosarcoma patients could be clearly divided into two clusters based on the 14 RAS-related prognostic genes (Figure 2(d)). In addition, patients with C2 had better overall survival than those with C1 ($P = 0.002$; Figure 2(e)). These results showed that 14 RAS-associated prognostic genes divided osteosarcoma patients into two molecular subtypes with different overall survival.

3.2. DEG and Functional Analyses. DEGs were identified between the two clusters, and functional analysis was performed to explore potential signaling mechanisms. A total of 198 DEGs were identified, of which 239 genes were downregulated and 126 genes were upregulated in C1 compared to C2 (Figure 3(a)). The GO enrichment analysis indicated that DEGs were concentrated in immune-related and other biological processes, which included focal adhesion, GTP binding, cytoskeletal motor activity, and cytosolic-matrix junctions (Figure 3(b)).

Furthermore, genes differentially expressed in the two clusters were identified and subsequently analyzed for their biological processes using the KEGG pathway to annotate their functions. The results showed that C1-enriched
pathways are mainly involved in immune response, stromal properties, and tumorigenesis (Figure 3(c)). Immune-related pathways included natural killer cell-mediated cytotoxicity, cytokine-cytokine receptor interactions, chemokine signaling, and TGF-β signaling. Pathways associated with stromal features include ECM receptor interactions, focal adhesion, and cell adhesion molecules. Oncogenic pathways included Hedgehog signaling, Notch signaling, MAPK signaling, Wnt signaling, and cancer pathways. (These results suggest that RAS signaling is clearly involved in cancer development, especially by affecting immune-related functions.)

3.3. Development of a Prognostic Gene Model. In total, 84 OS samples were compared with appropriate patients with complete survival data for matching. A univariate Cox regression analysis was used as a primary screen for survival-associated genes. The 14 genes (CALML3, CALML5, INSR, RRAS2, EFNA1, GNG4, IGF1R, GNG12, EGFR, EFNA5, RALB, HGF, PRKACB, and RAB5C) that met the criteria of \( P < 0.05 \) were retained for further analysis, and among them, 7 genes (CALML3, CALML5, INSR, RRAS2, EFNA1, GNG4, and IGF1R) were associated with increased risk with HRs > 1, while the other 7 genes (GNG12, EGFR, EFNA5, RALB, HGF, PRKACB, and RAB5C) were protective genes with HRs < 1 (Figure 4(a)).

Five genetic features were constructed based on the optimal \( \lambda \) values by Cox regression analysis with the least absolute shrinkage and selection operator (LASSO) (Figures 4(b) and 4(c)). Risk scores were calculated as follows: risk score = \((0.139 \times \text{GNG4 index}) + (-1.628 \times \text{RAB5C index}) + (-0.931 \times \text{PRKACB index}) + (0.447 \times \text{EFNA5 index}) + (0.288 \times \text{EFNA1 index})\). Based on the median calculated by the risk score formula, 84 patients were equally divided into low and high-risk subgroups (Figure 4(d)). A significant difference in OS time was detected between the low and high-risk groups (\( P < 0.001 \), Figure 4(d)). Using time-dependent receiver operating characteristic (ROC) analysis to assess the sensitivity and
Figure 4: Continued.
Figure 4: Construction of risk signature. (a) Univariate Cox regression analysis of OS for each pyroptosis-related gene, and 14 genes with $P < 0.05$. (b) LASSO regression of the 5 OS-related genes. (c) Cross-validation for tuning the parameter selection in the LASSO regression. (d) Kaplan–Meier curves for the OS of patients in the high and low-risk groups. (e) ROC curves demonstrating the predictive efficiency of the risk score. *$P$ value less than 0.05 is statistically significant.

Figure 5: Continued.
specificity of the prognostic model, we found that the area under the ROC curve (AUC) was 0.772 at 1 year, 0.917 at 2 years, and 0.837 at 3 years of survival (Figure 4(e)).

3.4. Independent Prognostic Value of the Risk Model. We used both univariate and multivariate Cox regression analyses to evaluate whether the risk score derived from the gene profile model could be used as an independent prognostic factor. Univariate Cox regression analysis showed that risk score was an independent predictor of poor survival (HR = 2.7, 95% CI: 1.9–3.8; Figure 5(a)). Multivariate analysis also showed that risk score was a prognostic factor for OS of patients after adjusting for other confounders (HR = 3.06, 95% CI: 2.09–4.5; Figure 5(b)). Furthermore, a heat map of clinical characteristics was generated (Figure 5(c)), which revealed a different distribution of patients’ age and survival status between low and high-risk subgroups (*P < 0.05).

3.5. Comparison of the Immune Activity between Subgroups. At first, the level of enrichment of 24 immune features representing the total immune activity in OS was quantified by ssGSEA. It was found that the immune cell distribution was significantly higher in the low-risk group than in the high-risk group (P < 0.05, Figure 6(a)). In addition, the ESTIMATE algorithm was performed to assess the time of both the groups, and the results showed that the low-risk group had significantly higher stromal score (P < 0.001, Figure 6(b)), immune score (P = 0.048, Figure 6(c)), ESTIMATE score (P < 0.001, Figure 6(d)), and significantly lower tumor purity compared to the high-risk group (Figure 6(e)). These results indicate that the constructed risk model has strong potential in predicting the prognosis of patients with osteosarcoma and is significantly associated with the time of osteosarcoma.

3.6. Risk-Based Modeling for Functional Analysis. As further effort to explore differences in gene function and pathways between subgroups classified according to the risk model, we extracted DEGs using the R package “Limma” using the criteria of P < 0.05 and |log2FC| ≥ 0.585. A total of 19 DEGs were identified between the low and high-risk groups. Of these, 13 genes were upregulated in the high-risk group, while the other 6 genes were downregulated. Gene ontology (GO) enrichment analysis was then performed based on these DEGs. The results indicated that the DEGs upregulated in the high-risk group was mainly correlated with the neuron death metabolic process, organization cascade, development of ERK1, contraction, smooth muscle healing, mesenchymal stem, Leydig luteinization, and amino acid oxidative oxygen (Figure 7(a)), while the DEGs downregulated in the low-risk group was mainly correlated with GTPase activity, GTP binding, guanyl nucleotide binding, and guanyl ribonucleotide binding (Figure 7(b)).
** Figure 6: Continued.**
4. Discussion

Osteosarcoma (OS) arises from malignant mesenchymal stem cells that generate the osteoid or immature bone [21]. For the past three decades, a combination of surgical resection and systemic chemotherapy has been the standard of care for OS, but little progress has been made since then. As the understanding of molecular mechanisms and pathways of OS has advanced, there is evidence that we are on the cusp of a paradigm shift.

Several large RNA-seq studies have revealed frequent RAS pathway abnormalities in malignancies, and the biology of the RAS pathway has been extensively reviewed [11, 22]. In view of that, RAS pathway inhibitors are available in the clinics for treating diverse cancer [12, 23]. RAN has been shown to play an important role in tumorigenesis and

![Figure 6: Immune analyses in the two subgroups. (a) Stromal score, (b) immune score, (c) ESTIMATE score, and (d) tumor purity calculated by the ESTIMATE algorithm. (e) Comparison of the enriching level of 29 immune-related cells evaluated by the ssGSEA algorithm, between low (yellow box) and high-risk (blue box) group. * $P < 0.05$; ** $P < 0.01$; and *** $P < 0.001$.](image)
development through bioinformatic approaches or experiments. For example, Feng and his colleagues analyzed the development of ovarian cancer into tumors through a series of bioinformatics and identified validated biomarkers [24, 25]. Nevertheless, a comprehensive analysis of the RAS pathway in OS is still scarce and the underlying mechanisms are not fully elucidated. In our study, we attempted to construct a prognostic model by defining disease subclassifications based on RAS-related genes. First, we identified two distinct subtypes based on 14 RAS-associated prognostic genes in the TARGET osteosarcoma cohort. Compared to patients with cluster C2, patients with cluster C1 had worse overall survival. Subsequently, KEGG pathways analysis revealed that pathways enriched in C1 were mostly associated with immune-related responses, stromal signatures, and oncogenesis, indicating that the RAS signaling clusters were highly correlated with osteosarcoma progression. Furthermore, a 5-gene signature including GNG4, RAB5C, PRKACB, EFNA5, and EFNA1 was established using LASSO analysis. Then, the robust predication of this RAS-related gene prognostic model was proved by ROC analysis. The aforementioned results displayed that identification of the RAS-related genes signature may provide new insight into treatment and clinical outcome predication.

RAS signaling pathway oncogenesis can be suppressed directly by targeting upstream and downstream molecules or RAS proteins directly [26]. The RAS proteins cycling between inactive and active states act as molecular switches in cell growth and differentiation [27]. The member of RAS superfamily of small GTPases has an essential function in tumor migration and invasion in osteosarcoma [28]. GO enrichment analysis demonstrated that the DEGs between RAS-related clusters were different biological processes, including GTP/GDP binding, focal adhesion, cytoskeletal motor activity, and cell-substrate junction. GTP/GDP binding regulates various cellular responses and is associated with tumor progression [29]. Thus, it may be pharmaceutically targeted in osteosarcoma treatment according to the above analysis.

RAS protein is activated by upstream receptors, such as members of the epidermal growth factor receptor (EGFR) family [30–32]. EGFR is a type of receptor tyrosine kinase (RTK) protein and located on the surface of solid tumors [33]. In this study, the EGFR expression level of osteosarcoma samples was verified by immunohistochemical staining. Currently, clinical trials are being conducted to examine the effectiveness of tyrosine kinase inhibitors (TKI) in the advanced osteosarcoma treatment. Multiple TKIs including sorafenib, regorafenib, and cabozantinib have...
proved activity and efficacy in patients with relapsed or metastatic osteosarcoma [13, 33, 34].

After activation of RAS proteins, downstream effector pathways are triggered, including RAS-RAF-MEK-ERK and RAS-P13K-AKT-mTOR [35]. Suppression of the ERK signaling pathway inhibits osteosarcoma invasion and promotes apoptosis in osteosarcoma [36]. There is increasing evidence that components of the P13K/AKT signaling pathway are often overactivated and are importantly associated with pulmonary metastasis in osteosarcoma [37]. Furthermore, osteosarcoma cell lines respond to therapeutic inhibition of the P13K/mTOR pathway both in vitro and in vivo [38]. Therefore, targeting RAS downstream effector pathways may have a potential role in the treatment of osteosarcoma, with several agents showing promise as antimetastatic agents [39–42].

RAS pathway has not yet been fully understood in terms of its effect on immune infiltration and TME in osteosarcoma. Osteosarcoma patients with lung metastases had significantly increased expression level of exosomal PD-L1 than those with localized disease, and preclinical studies suggested that osteosarcoma may be susceptible to immunotherapy [43, 44]. Besides, it is worth mentioning that macrophages and other types of immune cells should receive more attention in osteosarcoma rather than T cells [45]. In this study, we discovered that the characteristics of the TME and the relative abundance of 24 immune infiltration cells differed significantly between two risk groups. Those in the RAS low-risk group had a better prognosis, showing a higher infiltration of macrophages and CD8+-infiltrating lymphocytes. In addition, the RAS low-risk group had lower tumor purity but higher ESTIMATE scores. These results suggest that the established RAS-related osteosarcoma risk model is significantly associated with TME and immune infiltration and will provide new ideas for immunotherapy. There are several limitations in our study. First, the RAS-related prognosis model based on TARGET database was not validated externally due to the scarcity of osteosarcoma data. Second, the osteosarcoma samples of the risk model were retrospectively extracted from the public database, and there was existing inherent case selection bias in this study. Finally, additional in vitro and in vivo experiments are needed to validate RAS-associated prognostic genes in osteosarcoma.

5. Conclusion

In conclusion, our comprehensive analysis of the RAS pathway in osteosarcoma revealed its significant value in prognosis. Besides, RAS-related gene subtypes were involved in different molecular pathways related to tumor progression and immune infiltration. These findings spotlight the important clinical implications of RAS, and further research is required to investigate the therapeutic value about RAS-related gene in osteosarcoma.

Data Availability

The datasets analyzed during the current study are available in the TCGA repository, https://www.cancergeno.me.nih.gov/.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

All authors have made a substantial, direct, and intellectual contribution to the work and approved it for publication. Qin Chen and Xueliang Zhou contributed equally to this work.

Acknowledgments

The authors would like to acknowledge TCGA for free use.

References

[1] W. H. Cho, W. S. Song, D. G. Jeon et al., “Differential presentations, clinical courses, and survivals of osteosarcomas of the proximal humerus over other extremity locations,” Annals of Surgical Oncology, vol. 17, no. 3, pp. 702–708, 2010.
[2] E. E. Pakos, A. D. Nearchou, R. J. Grimer et al., “Prognostic factors and outcomes for osteosarcoma: an international collaboration,” European Journal of Cancer, vol. 45, no. 13, pp. 2367–2375, 2009.
[3] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer statistics, 2022,” CA: A Cancer Journal for Clinicians, vol. 72, no. 1, pp. 7–33, 2022.
[4] L. Mirabello, R. J. Troisi, and S. A. Savage, “Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program,” Cancer, vol. 115, no. 7, pp. 1531–1543, 2009.
[5] G. Ottaviani and N. Jaffe, “The epidemiology of osteosarcoma,” Cancer Treatment and Research, vol. 152, pp. 3–13, 2009.
[6] J. Ritter and S. S. Bielack, “Osteosarcoma,” Annals of Oncology, vol. 21, pp. i320–i325, 2010.
[7] M. S. Isakoff, S. S. Bielack, P. Meltzer, and R. Gorlick, “Osteosarcoma: current treatment and a collaborative pathway to success,” Journal of Clinical Oncology, vol. 33, no. 27, pp. 3029–3035, 2015.
[8] R. Belayneh, M. S. Fourman, S. Bhogal, and K. R. Weiss, “Update on osteosarcoma,” Current Oncology Reports, vol. 23, no. 6, pp. 71, 2021.
[9] X. Chen, A. Bahrami, A. Pappo et al., “Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma,” Cell Reports, vol. 7, no. 1, pp. 104–112, 2014.
[10] M. Malumbres and M. Barbacid, “RAS oncogenes: the first 30 years,” Nature Reviews Cancer, vol. 3, no. 6, pp. 459–465, 2003.
[11] G. M. Ney, L. McKay, C. Koschmann, R. Mody, and Q. Li, “The emerging role of ras pathway signaling in pediatric cancer,” Cancer Research, vol. 80, no. 23, pp. 5155–5163, 2020.
[12] D. K. Simanshu, D. V. Nisley, and F. McCormick, “RAS proteins and their regulators in human disease,” Cell, vol. 170, no. 1, pp. 17–33, 2017.
[13] G. Grignani, E. Palmerini, P. Dileo et al., “A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian sarcoma group study,” Annals of Oncology, vol. 23, no. 2, pp. 508–516, 2012.
[14] M. P. Patricelli, M. R. Janes, L. S. Li et al., “Selective inhibition of oncogenic KRAS output with small molecules targeting the
inactive state,” Cancer Discovery, vol. 6, no. 3, pp. 316–329, 2016.

[15] Y. Xie, Z. Cao, E. W. Wong et al., “COPI/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors,” Journal of Clinical Investigation, vol. 128, no. 4, pp. 1442–1457, 2018.

[16] S. Wei, Z. Jagni, K. X. Xiang et al., “PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers,” Cancer Research, vol. 69, no. 10, pp. 4286–4293, 2009.

[17] K. Yoshihara, M. Shahmoradgoli, E. Martinez et al., “Inferring tumour purity and stromal and immune cell admixture from expression data,” Nature Communications, vol. 4, no. 1, 2013.

[18] S. Feng, H. Yin, K. Zhang et al., “Integrated clinical characterization and genomic interpretation of genome-wide expression profiles,” BMC Bioinformatics, vol. 14, no. 1, 2013.

[19] G. Yu, L. G. Wang, Y. Han, and Q. Y. He, “Clusterprofiler: an R package for comparing biological themes among gene clusters,” OMICS: A Journal of Integrative Biology, vol. 16, no. 5, pp. 284–287, 2012.

[20] A. Subramanian, P. Tamayo, V. K. Mootha et al., “Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 43, pp. 15545–15550, 2005.

[21] C. A. Arndt, P. S. Rose, A. L. Folpe, and N. N. Laack, “Common musculoskeletal tumors of childhood and adolescence,” Mayo Clinic Proceedings, vol. 87, no. 5, pp. 475–487, 2012.

[22] H. Qian, T. Lei, Y. Hu, and P. Lei, “Expression of lipid-metabolism genes is correlated with immune microenvironment and predicts prognosis in osteosarcoma,” Frontiers in Cell and Developmental Biology, vol. 9, Article ID 673827, 2021.

[23] M. B. Ryan and R. B. Corcoran, “Therapeutic strategies to target RAS-mutant cancers,” Nature Reviews Clinical Oncology, vol. 15, no. 11, pp. 709–720, 2018.

[24] S. Feng, T. Xia, Y. Ge et al., “Computed tomography imaging-based radiogenomics analysis reveals hypoxia patterns and immunological characteristics in ovarian cancer,” Frontiers in Immunology, vol. 13, Article ID 868067, 2022.

[25] S. Feng, H. Yin, K. Zhang et al., “Integrated clinical characteristics and omics analysis identifies a ferroptosis and iron-metabolism-related lncRNA signature for predicting prognosis and therapeutic responses in ovarian cancer,” Journal of Ovarian Research, vol. 15, no. 1, 2022.

[26] K. Chen, Y. Zhang, L. Qian, and P. Wang, “Emerging strategies to target RAS signaling in human cancer therapy,” Journal of Hematology & Oncology, vol. 14, no. 1, p. 116, 2021.

[27] J. Cherfils and M. Zeghouf, “Regulation of small GTPases by GEFs, GAPs, and GDIs,” Physiological Reviews, vol. 93, no. 1, pp. 269–309, 2013.

[28] J. Wu, W. Du, X. Wang et al., “Ras-related protein Rap2c promotes the migration and invasion of human osteosarcoma cells,” Oncology Letters, vol. 15, no. 4, pp. 5352–5358, 2018.

[29] R. B. Haga and A. J. Ridley, “Rho GTPases: regulation and roles in cancer cell biology,” Small GTPases, vol. 7, no. 4, pp. 207–221, 2016.

[30] J. P. O’Bryan, “Pharmacological targeting of RAS: recent success with direct inhibitors,” Pharmacological Research, vol. 139, pp. 503–511, 2019.

[31] J. S. Whelan and L. E. Davis, “Osteosarcoma, chondrosarcoma, and chordoma,” Journal of Clinical Oncology, vol. 36, no. 2, pp. 188–193, 2018.

[32] N. Normanno, A. De Luca, C. Bianco et al., “Epidermal growth factor receptor (EGFR) signaling in cancer,” Gene, vol. 366, no. 1, pp. 2–16, 2006.

[33] A. Italiano, O. Mir, S. Mathoulin-Pelissier et al., “Cabozantinib in patients with advanced ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial,” The Lancet Oncology, vol. 21, no. 3, pp. 446–455, 2020.

[34] L. E. Davis, V. Bolejack, C. W. Ryan et al., “Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma,” Journal of Clinical Oncology, vol. 37, no. 16, pp. 1424–1431, 2019.

[35] A. A. Krygowska and E. Castellano, “PI3K: a crucial piece in the RAS signaling puzzle,” Cold Spring Harb Perspect Med, vol. 8, no. 6, Article ID a031450, 2018.

[36] C. Yang, Y. Tian, F. Zhao et al., “Bone microenvironment and osteosarcoma metastasis,” International Journal of Molecular Sciences, vol. 21, no. 19, p. 6985, 2020.

[37] J. Zhang, X. H. Yu, Y. G. Yan, C. Wang, and W. J. Wang, “PI3K/Akt signaling in osteosarcoma,” Clinica Chimica Acta, vol. 444, pp. 182–192, 2015.

[38] J. A. Perry, A. Kiezen, P. Tonzi et al., “Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 51, pp. E5564–E5573, 2014.

[39] M. Tsubaki, Y. Yamazoe, M. Yanae et al., “Blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathways by statins reduces the expression of bFGF, HGF, and TGF-beta as angiogenic factors in mouse osteosarcoma,” Cytokine, vol. 54, no. 1, pp. 100–107, 2011.

[40] C. L. Wu, H. C. Tsai, Z. W. Chen et al., “Ras activation mediates WISP-1-induced increases in cell motility and matrix metalloproteinase expression in human osteosarcoma,” Cellular Signalling, vol. 25, no. 12, pp. 2812–2822, 2013.

[41] M. Tsubaki, T. Satou, T. Itoh et al., “Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway,” Toxicology and Applied Pharmacology, vol. 259, no. 3, pp. 402–410, 2012.

[42] C. Wang, X. Zhou, W. Li et al., “Macrophage migration inhibitory factor promotes osteosarcoma growth and lung metastasis through activating the RAS/MAPK pathway,” Cancer Letters, vol. 403, pp. 271–279, 2017.

[43] J. Wang, H. Zhang, X. Sun et al., “Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients,” Journal of Nanobiotechnology, vol. 18, no. 1, p. 151, 2020.

[44] M. F. Wedekind, L. M. Wagner, and T. P. Cripe, “Immuno-therapy for osteosarcoma: where do we go from here?” Pediatric Blood and Cancer, vol. 65, no. 9, Article ID e27227, 2018.

[45] C. Chen, L. Xie, T. Ren, Y. Huang, J. Xu, and W. Guo, “Immuno-therapy for osteosarcoma: fundamental mechanism, rationale, and recent breakthroughs,” Cancer Letters, vol. 500, pp. 1–10, 2021.